Your browser doesn't support javascript.
loading
The MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study.
LoRusso, Patricia; Yamamoto, Noboru; Patel, Manish R; Laurie, Scott A; Bauer, Todd M; Geng, Junxian; Davenport, Teffany; Teufel, Michael; Li, Jian; Lahmar, Mehdi; Gounder, Mrinal M.
Afiliação
  • LoRusso P; Yale University School of Medicine, Yale Cancer Center, New Haven, Connecticut.
  • Yamamoto N; National Cancer Center Hospital, Department of Experimental Therapeutics, Tokyo, Japan.
  • Patel MR; Sarah Cannon Research Institute, Florida Cancer Specialists and Research Institute, Sarasota, Florida.
  • Laurie SA; The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada.
  • Bauer TM; Sarah Cannon Research Institute Tennessee Oncology, Nashville, Tennessee.
  • Geng J; Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut.
  • Davenport T; Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut.
  • Teufel M; Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut.
  • Li J; Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut.
  • Lahmar M; Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
  • Gounder MM; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical School, New York, New York.
Cancer Discov ; 13(8): 1802-1813, 2023 08 04.
Article em En | MEDLINE | ID: mdl-37269344
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Segunda Neoplasia Primária / Lipossarcoma / Neoplasias / Antineoplásicos Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Segunda Neoplasia Primária / Lipossarcoma / Neoplasias / Antineoplásicos Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article